ClinicalTrials.gg
Enrolling by invitationNCT06668376Updated Nov 1, 2024

A Study to Evaluate the Incrediwear Products Immediately After ACL Repair

An interventional study of Leg Sleeve and Placebo in Anterior Cruciate Ligament Tear and Medial Collateral Ligament, sponsored by Texas Bone and Joint. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Texas Bone and Joint · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States — 44 open to participants now, 62 under way, 3 of them phase 3. Anterior Cruciate Ligament Injuries · United States.

Planned enrollment
40th of 152
90 · median 50
Started
2024
with 14 others
No phase
113 of 176
27 open now
Primary completion
2026-10
later than 18 of 61 live
Registered
157th of 176
by date

Among the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, this one is the 40th largest by planned enrollment of the 152 interventional ones that give a count, is one of 15 that started in 2024, is one of 113 with no phase, reaches primary completion later than 18 of the 61 other live ones, and was the 157th registered.

Anterior Cruciate Ligament Injuries

627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.

Browse Anterior Cruciate Ligament Injuries studies →

Open to participants now

44 of the 176 studies in Anterior Cruciate Ligament Injuries with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies in Anterior Cruciate Ligament Injuries with a site in United States, or all of them as a file.
02

Study summary

To assess the benefits of using the Incrediwear knee products after ACL or ACL+MCL arthroscopic surgery, on the postoperative pain, range of motion and effusion. The study team will compare patients with Incrediwear products, or placebo Incrediwear products, or no products during the first 6-month postoperative period. The group that does not wear the Incrediwear or placebo products is considered the standard of care control group and will proceed with the normal standard of care compression hose.

Read the detailed description

After knee surgery, the participant will be randomly assigned to one of the three groups. The participant will have a 1-in-3 chance of being assigned to each group. The products will be placed on the participant by the hospital staff according to the random assignment sent with the surgical packet.

Study Screening/pre-operative appointment

  • The surgeon confirms the participant meets the inclusion criteria and are scheduled for surgery in the next few weeks, and how the participant may be eligible to participate in the study.
  • The surgeon will discuss the study and possible risks/benefits of being in the research.

    • Day of surgery
  • The study packet will be sent to the hospital by the clinical staff. The packet will include a study number assignment, the products assigned the study number, and the patient study journal. The participant, surgeon, and hospital staff will not know which group the participant are in, with the exception of the standard of care control group, as this group will wear the hospital-issued compression hose.

    • Postoperative Recovery
  • Subjective: Patient rates surgical site pain, on a 0-10 VAS pain scale. Patients will record pain medication type and quantity taken in a daily pain diary.
  • Objective: Surgical extremity range of motion, and surgical extremity knee effusion, measured by either the Physical Therapist or the surgeon at the postop appointment.
  • Measurements will be taken at; Preop appointment, Postop Day 0, Day 3, Day 7, Day 14, Day 21, Day 30 (1 month), Day 45, Day 60 (2 month), Day 100 (3 month), and Day 180 (6 month).
03

Conditions studied

  • Anterior Cruciate Ligament Tear
  • Medial Collateral Ligament

Keywords

  • Anterior Cruciate Ligament Tear
  • Medial Collateral Ligament Tear
  • Anterior Cruciate Ligament Repair
  • Medial Collateral Ligament Repair
  • Arthroscopic surgery
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consented to protocol
  • Compliant protocol
  • less than 35
  • Undergoing ACL or ACL+MCL within 30 days

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Rheumatoid Arthritis
  • Poorly controlled diabetes (HgA1c > 7.5)
  • Previous blood clots
  • greater than 35
  • Varicosities on operative leg
  • Pain management patient
  • Prior knee surgery to the operative / study knee
  • Worker's Comp patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
90 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Product

    Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear products and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.

    Device: Placebo

  • Active comparator
    Incrediwear Product

    Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear products and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.

    Device: Leg Sleeve

Interventions

  • DeviceLeg Sleeve

    Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.

  • DevicePlacebo

    Once the informed consent has occurred, the patient will be invited to enroll in the study. The patient will be shown the Incrediwear product (Leg Sleeve) and given instructions. Participants will randomly be assigned treatment type in addition to the standard of care procedure they will be instructed to follow (active vs. placebo vs standard of care alone) based on surgery type. An equal number of patients from each primary condition type (ACL or ACL+MCL) will be assigned to each treatment type. The study will be double blinded as to the active vs placebo groups.

06

What researchers measure

Primary outcomes

  1. Visual Analogue Scale

    The pain VAS is a unidimensional measure of pain intensity, used to record patients' pain progression, or compare pain severity between patients with similar conditions. The minimum number is zero meaning no pain and maximum number is 10 meaning the most pain the patient has every felt in their entire life. Lower scores are ideal while higher scores are indicative of the patient in a lot of pain.

    Time frame: Preop appointment, Postop Day 0, Day 3, Day 7, Day 14, Day 21, Day 30 (1 month), Day 45, Day 60 (2 month), Day 100 (3 month), and Day 180 (6 month)

  2. Range of Motion Measured by a Goniometer

    Knee flexion and extension to assess mobility and functionality of the knee joint. The knee joint's range of motion (ROM) is an important clinical parameter used in knee assessment. Knee flexion should be about 150 degrees and knee extension should be about zero degrees (American Medical Association). Lower degrees of flexion are not ideal while higher degrees of extension are not optimal.

    Time frame: Preop appointment, Postop Day 0, Day 3, Day 7, Day 14, Day 21, Day 30 (1 month), Day 45, Day 60 (2 month), Day 100 (3 month), and Day 180 (6 month)

07

Study locations

1 site
08

References and documents

Related links

Individual participant data

Plan to share: Undecided — Pre-approval to share data and data results must be obtained by the corporation.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2026, 24 months after the start.

Of 279 non-industry interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's planned 24 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 14 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2024
First posted
Oct 31, 2024
StartActual
Oct 29, 2024
Primary completionEst.
Oct 29, 2026
CompletionEst.
Nov 1, 2026
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06668376
Lead sponsor
Texas Bone and Joint
Collaborators
INCREDIWEAR HOLDINGS, INC., Medical City Denton
Responsible party
Christopher Flowers, MD (Orthopaedic Surgeon, Texas Bone and Joint) — Principal investigator
First posted
Oct 31, 2024
Start date
Oct 29, 2024
Primary completion
Oct 29, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Nov 1, 2024

Study contacts

Christopher Flowers, MD, MS
principal investigator · Texas Bone and Joint

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion